• West Pharmaceutical Services entered a USD 950 million credit agreement on October 26, 2026, with Bank of America as administrative agent.
• The five-year, unsecured financing comprises a USD 750 million revolving credit facility and a USD 200 million term loan facility.
• Proceeds repaid USD 130 million outstanding under the 2019 credit agreement, which was terminated without early termination penalties.
• Remaining borrowings are intended for general corporate purposes, including capital expenditures, permitted acquisitions and stock repurchases.
• The agreement caps net leverage at 3.50 times, rising to 4.00 times during material acquisition periods, subject to limitations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. West Pharmaceutical Services Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000105770-26-000114), on October 26, 2026, and is solely responsible for the information contained therein.